CNS vs IVZ: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

IVZ is the larger of the two ($11.77B market cap): the incumbent the market prices for continued execution (8.09x forward earnings, beta 1.65). CNS is the smaller challenger ($3.34B), actually pricier on forward earnings (18.42x): more room to run, but more to prove. On the numbers, IVZ leads on both counts: faster expected revenue growth (7% vs 1%) and a lower forward P/E (8.09x vs 18.42x). The case for CNS rests on its own driver (Interest rates and real assets): if you believe in that, CNS fits; if you believe in what the numbers show today, IVZ does.

CNS vs IVZ: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricCNSIVZWhat it tells you
Market cap$3.34B$11.77BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E18.428.09Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.181.65Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range23% of range42% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book5.501.16How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: IVZ is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how CNS and IVZ affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CNS and IVZ share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CNS and IVZ exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Cohen & Steers (CNS) do?

Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. It organized the first US real estate securities mutual fund and remains one of the largest managers of REIT securities in the world, with roughly two-thirds of assets in listed real estate. The firm earns management fees on the assets it runs across open-end funds, closed-end funds, institutional accounts, and newer vehicles like its non-traded REIT (CNSREIT), which in October 2026 bought the Manchester Village Shopping Center in Rock Hill, South Carolina and in November joined DLC to buy the West Street Shopping Center in Keene, New Hampshire.

Full CNS guide

What does Invesco Ltd (IVZ) do?

Invesco Ltd. is a global independent investment management firm that manages money for retail and institutional clients across equities, fixed income, alternatives, and multi-asset strategies. It distributes through mutual funds, separately managed accounts, institutional mandates, and a large ETF business, and it is best known as the sponsor of Invesco QQQ, one of the largest and most heavily traded ETFs in the world. Because it earns fees on the assets it manages, Invesco's revenue moves with two things: the level of markets (which lifts or lowers asset values) and net client flows (money coming in or leaving).

Full IVZ guide

CNS vs IVZ: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • CNS drivers: Interest rates and real assets; Return to organic growth.
  • IVZ drivers: QQQ conversion unlocks new fees; Record AUM and durable inflows.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: CNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings. For IVZ, the dominant risk is market sensitivity: as a fee-on-assets business, Invesco's revenue and profits fall when equity and bond markets drop, so a sustained downturn would cut AUM and earnings quickly regardless of execution.

CNS or IVZ: which should you pick?

If the story you believe is CNS's (Interest rates and real assets), CNS is the more direct way to own it; if it is IVZ's (QQQ conversion unlocks new fees), IVZ is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CNS and IVZ guides.

CNS vs IVZ: the full fundamentals

CNS. As of November 20, 2026, CNS trades at about 20 times trailing and 18.5 times forward earnings with a dividend yield near 4.1%, cheaper than in October after a further slide toward its 52-week low of about $58.39. AUM actually rose in October on market gains, so the gap between a recovering asset base and a falling share price is the current debate, alongside softer flows. The three analysts in the digest hold a mean target near $66.67 with a hold rating, close to the current price.

IVZ. Figures are approximate and tied to the asOf date; verify live numbers before acting. At about $26.81 on November 20, 2026, Invesco trades near 8.1 times forward earnings and 1.2 times book with a yield near 3.1%, a lower multiple than in October after an 18% three-month decline, for an asset manager whose adjusted EPS is expected to grow about 37% in 2026; GAAP results show a trailing loss, so there is no meaningful trailing P/E. For an asset manager, AUM, flows, and fee rate matter more than a single quarter's EPS. The analyst mean target is about $35.13 across 15 analysts, and the next report is expected around January 26, 2027.

Headline figures (approximate, November 2026): CNS shows revenue (ttm) ~$600M, +11% YoY in Q3 2026, revenue (q3 2026) ~$157.4M, adjusted eps (q3 2026) ~$0.89 vs ~$0.90 consensus, net income (ttm) / net margin ~$169M / ~28%; IVZ shows revenue (ttm) ~$7.1 billion; latest quarter up ~14% YoY, adjusted eps (q3 2026) ~$0.72 vs ~$0.74 consensus, net income (ttm, gaap) ~-$316 million, operating margin (ttm) ~21% GAAP.

The bottom line: CNS vs IVZ

CNS and IVZ are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined CNS and IVZ exposure against your real portfolio. It is not an investment adviser.

Wondering how CNS or IVZ fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Cohen & Steers

Ask Walnut's AI anything about CNS and see how it fits what you own.

FAQ

What is the difference between CNS and IVZ?

+

Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. Invesco Ltd. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is CNS or IVZ the better stock?

+

Neither is universally better. IVZ is the larger incumbent; CNS is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, CNS or IVZ?

+

On forward P/E (as of November 2026), CNS trades at 18.42x and IVZ at 8.09x, so IVZ is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both CNS and IVZ?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of CNS vs IVZ?

+

CNS: CNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings. Its concentration in real estate and rate-sensitive income means a reversal to higher-for-longer rates, or a rotation away from REITs and preferreds, could trigger outflows and market depreciation at the same time; the AUM declines reported for August and September 2026 show that dynamic at work. EPS has come in a cent or a few cents below consensus in three of the last four quarters, and October 2026 brought net outflows of about $209 million. The dividend absorbs about 81% of trailing earnings, which leaves less cushion if profits dip. The active-management fee model faces secular pressure from low-cost passive and index products, and net flows can turn negative in stressed markets. Newer private and non-traded initiatives add execution and liquidity risk, and results can be lumpy quarter to quarter. IVZ: The dominant risk is market sensitivity: as a fee-on-assets business, Invesco's revenue and profits fall when equity and bond markets drop, so a sustained downturn would cut AUM and earnings quickly regardless of execution. Fee compression is structural, with passive and ETF price wars (Invesco itself is cutting the QQQ fee) pressuring industry margins over time. Flows can reverse: eleven quarters of inflows can turn to outflows if performance lags or sentiment shifts. Heavy reliance on a single flagship product, QQQ, concentrates risk in the Nasdaq-100 and the tech-heavy names that drive it, and QQQ also faces new ETF competition. The private-markets push adds execution and partnership-dependency risk, and the firm carries debt and prior preferred obligations that constrain flexibility in a downturn. The QQQ upside is debated rather than assumed: in October 2026 analysts moved targets in both directions (Autonomous Research to $30 from $31, JPMorgan to $32 from $29.50), Q3 adjusted EPS then missed consensus by two cents, and the stock fell about 18% over three months to November 20 even as Mizuho initiated at outperform with a $37 target.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CNS or IVZ; figures are approximate and dated (as of November 2026). Verify current data before investing.